Idiosyncratic reactions to drugs: can medicine response profiles provide a dynamic drug surveillance system?
Over the next few years it will be possible to use advances in single nucleotide polymorphism map technology to correlate information from patients' DNA with their response to medicines. This provides significant opportunities to enhance current drug surveillance systems by collecting data that would enable rare serious adverse events to be predicted in subsequent patients before the medicine is prescribed. Reasonable discussion regarding perceived or real barriers to this surveillance concept is required to realize the significant patient benefits which will accrue from this system.
Roses
A D
AD
Genetics Directorate, Glaxo Wellcome plc, Greenford Middlesex, UK. adr6941@Glaxowellcome.com
D064420:Drug-Related Side Effects and Adverse Reactions; D005826:Genetics, Medical; D005838:Genotype; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods*; D011358:Product Surveillance, Postmarketing